2011
Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus
Shahabi S, Pellicciotta I, Hou J, Graceffa S, Huang GS, Samuelson RN, Goldberg GL. Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus. Rare Tumors 2011, 3: 41. PMID: 22355496, PMCID: PMC3282446, DOI: 10.4081/rt.2011.e41.Peer-Reviewed Original ResearchLarge cell neuroendocrine carcinomaNeuroendocrine tumorsUterine corpusGenital tractLarge cell neuro endocrine carcinomaLarge cell neuroendocrine tumorNeuro-endocrine carcinomaPrimary neuroendocrine tumorCell neuroendocrine carcinomaFemale genital tractPotential future therapeuticsEndocrine carcinomaAggressive treatmentInitial diagnosisUterine cervixNeuroendocrine carcinomaTreatment optionsRare caseClinical utilityChromogranin AOptimal managementTumorsFuture therapeuticsCervixCarcinoma
2009
Extragenital adenosarcoma: A case report, review of the literature, and management discussion
Huang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL. Extragenital adenosarcoma: A case report, review of the literature, and management discussion. Gynecologic Oncology 2009, 115: 472-475. PMID: 19712965, PMCID: PMC4451226, DOI: 10.1016/j.ygyno.2009.07.033.Peer-Reviewed Case Reports and Technical NotesConceptsSarcomatous overgrowthLiposomal doxorubicinHigh-grade bowel obstructionMixed epithelial-mesenchymal tumorsComplete clinical responseInitial cytoreductive surgeryCompletion of chemotherapyFavorable prognostic factorAggressive clinical behaviorCoexistent endometriosisConcurrent endometriosisBowel obstructionCytoreductive surgeryClinical responseExtragenital sitesPrognostic factorsCase reportClinical behaviorSecond surgeryMüllerian adenosarcomaRare caseAdenosarcomaEndometriosisChemotherapySurgery